<DOC>
	<DOCNO>NCT00241423</DOCNO>
	<brief_summary>The purpose study test hypothesis patient type 2 diabetes , addition exenatide result low time-averaged serum glucose 24-hour period , compare placebo .</brief_summary>
	<brief_title>Effect Exenatide 24-Hour Blood Glucose Profile Compared With Placebo Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Subject HbA1c 7.0 % 10.0 % , inclusive . Subject body mass index ( BMI ) &gt; 25 kg/m^2 &lt; 50 kg/m^2 . Subject stable dose metformin metformin plus thiazolidinedione . Subject treat follow medication : *exogenous insulin 1 week within 3 month screen , *sulfonylureas meglitinides within 2 month screen , *alphaglucosidase inhibitor within 2 month screen , *pramlintide acetate injection within 2 month screen . Subject receive exenatide , GLP1 analog , DPPIV inhibitor , participate study previously .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>